Further Expansion in US for Qlucore
News May 18, 2016
The appointment of Yana Stackpole, based in Boston MA, will help drive new business on the East Coast, and to support Qlucore’s expanding client base. Yana is a bench biologist with a PhD in biophysics and has an MSc in business management. Her areas of interest are big data analysis, genomics, biotechnology, discovery and partnerships.
The US is an important and fast-growing market for Qlucore, which has seen a rapid increase in new contracts for its Qlucore Omics Explorer software. In 2014 Qlucore opened an office in New York, strengthening its position in the States, and allowing it to capitalize on the strength of the biotech and pharma industries as well as all universities and government driven research institutes. Qlucore is a member of the Swedish American Chamber of Commerce, the preeminent Swedish-American transatlantic organization dedicated to the promotion, advancement, and protection of direct commercial relations between the United States and Sweden. Qlucore is also a member of the Massachusetts Biotechnology Council, an association of more than 600 biotechnology companies, universities, academic institutions and others dedicated to advancing cutting edge research.
Qlucore Omics Explorer is unique in that it allows the actual researchers – the people with the most biological insight – to study their own data and to look for patterns and structures. As a result, researchers do not need to be statistics or computer experts in order to use Qlucore Omics Explorer effectively.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE